January 18, 2007 -- On January 16, Dendreon announced the FDA accepted its BLA for Provenge and granted it priority review status. Provenge is an investigational active cellular immunotherapy (ACI) for the treatment of hormone-refractory prostate cancer (AIPC). Cancer vaccines have a long history with tantalizing results but few outright successes. However, the field is maturing and good results may be forthcoming before the end of the decade. Unfortunately, the history of Provenge clinical trials is full of ups and downs. Will the results be enough to convince an FDA panel? We take a look...
